Biora Therapeutics Plans To Submit Updated IND Application For BT-600; Says FDA Requested Additional Information On IND For BT-600
Portfolio Pulse from Benzinga Newsdesk
Biora Therapeutics plans to submit an updated Investigational New Drug (IND) application for BT-600, following a request for additional information from the FDA. The company could potentially submit the updated filing as early as this week.
October 23, 2023 | 9:32 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Biora Therapeutics' updated IND application for BT-600 could potentially impact the company's stock. The FDA's request for additional information indicates regulatory scrutiny, which could affect investor sentiment.
The FDA's request for additional information on Biora Therapeutics' IND application for BT-600 indicates regulatory scrutiny. This could potentially affect investor sentiment and the company's stock price. However, the impact is uncertain until the FDA's response to the updated application is known.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100